Brookfield Infrastructure Partners LP vs Zimmer Biomet Holdings Inc — how do they compare? Brookfield Infrastructure Partners LP trades at $39.75 (market cap $18.10B), while Zimmer Biomet Holdings Inc trades at $95.39 (market cap $18.55B). The key difference: Brookfield Infrastructure Partners LP and Zimmer Biomet Holdings Inc are close in size by market cap, and Brookfield Infrastructure Partners LP pays the higher dividend (4.62%). Which is the better fit depends on your goals.
| BIP | ZBH | |
|---|---|---|
Market Cap | $18.10B | $18.55B |
Sector | Industrials | Health |
52-Week High | $42.62 | $107.71 |
52-Week Low | $29.81 | $79.58 |
Enterprise Value | $77.05B | $25.61B |
Dividend Yield | 4.62% | 0.99% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Trailing returns across standard periods
Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.
Read more on BIP →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →